Development of Sarcoidosis during Etanercept Therapy
This report describes a 65-year-old woman who developed granulomatous lesions consistent with sarcoidosis during etanercept therapy for rheumatoid arthritis. Hilar and mediastinal lymphadenopathy and multiple nodules in both lung fields developed 21 months after administration of etanercept. Noncase...
Gespeichert in:
| Veröffentlicht in: | Internal Medicine 2008, Vol.47(11), pp.1021-1025 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1025 |
|---|---|
| container_issue | 11 |
| container_start_page | 1021 |
| container_title | Internal Medicine |
| container_volume | 47 |
| creator | Ishiguro, Takashi Takayanagi, Noboru Kurashima, Kazuyoshi Matsushita, Aya Harasawa, Keiji Yoneda, Koichiro Tsuchiya, Noriko Miyahara, Yousuke Yamaguchi, Shozaburo Yano, Ryozo Tokunaga, Daidou Saito, Hiroo Ubukata, Mikio Yanagisawa, Tsutomu Sugita, Yutaka Kawabata, Yoshinori |
| description | This report describes a 65-year-old woman who developed granulomatous lesions consistent with sarcoidosis during etanercept therapy for rheumatoid arthritis. Hilar and mediastinal lymphadenopathy and multiple nodules in both lung fields developed 21 months after administration of etanercept. Noncaseating epithelioid cell granulomas consistent with sarcoidosis were detected in a lung biopsy specimen and in the parietal pleura obtained via thoracotomy. Diseases showing similar histologic changes were excluded, and a diagnosis of sarcoidosis was made. Etanercept was discontinued, which resulted in symptomatic relief, improvement of oxygenation and radiologic findings. There is substantial evidence of tumor necrosis factor-alpha involvement in the induction and maintenance of granuloma formation; however, we should keep in mind that granulomatous disease, such as sarcoidosis, can develop during treatment with a tumor necrosis factor-alpha blocking agent, such as etanercept. |
| doi_str_mv | 10.2169/internalmedicine.47.0602 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_907172762</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>907172762</sourcerecordid><originalsourceid>FETCH-LOGICAL-c614t-6a6c884979a6f773d953d0f2dab06754464ccadd0f15413e0aca68ccde12dd2e3</originalsourceid><addsrcrecordid>eNptkE9PwzAMxSMEYmPwFVBvnDriNE3aIxrjjzRpB8Y5yhJ3y9S1JWmR9u3ptGpIiIst2b_3bD1CIqBTBiJ_dFWLvtLlHq0zrsIpl1MqKLsgY0h4HkuWpJdkTHPIYtaXEbkJYUdpksmcXZMRZCmjAHxM-DN-Y1k3e6zaqC6iD-1N7WwdXIhs5121ieatrtAbbNpotUWvm8MtuSp0GfBu6BPy-TJfzd7ixfL1ffa0iI0A3sZCC5NlPJe5FoWUic3TxNKCWb2mQqacC26Mtv0IUg4JUm20yIyxCMxahsmEPJx8G19_dRhatXfBYFn2D9VdUDmVIJkUrCezE2l8HYLHQjXe7bU_KKDqGJn6G5niUh0j66X3w5Fu3S9_hUNGPbA8AbvQ6g2eAe1bZ0r81xlgqEAZnEmz1V5hlfwASbeKYQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>907172762</pqid></control><display><type>article</type><title>Development of Sarcoidosis during Etanercept Therapy</title><source>J-STAGE Free</source><source>MEDLINE</source><creator>Ishiguro, Takashi ; Takayanagi, Noboru ; Kurashima, Kazuyoshi ; Matsushita, Aya ; Harasawa, Keiji ; Yoneda, Koichiro ; Tsuchiya, Noriko ; Miyahara, Yousuke ; Yamaguchi, Shozaburo ; Yano, Ryozo ; Tokunaga, Daidou ; Saito, Hiroo ; Ubukata, Mikio ; Yanagisawa, Tsutomu ; Sugita, Yutaka ; Kawabata, Yoshinori</creator><creatorcontrib>Ishiguro, Takashi ; Takayanagi, Noboru ; Kurashima, Kazuyoshi ; Matsushita, Aya ; Harasawa, Keiji ; Yoneda, Koichiro ; Tsuchiya, Noriko ; Miyahara, Yousuke ; Yamaguchi, Shozaburo ; Yano, Ryozo ; Tokunaga, Daidou ; Saito, Hiroo ; Ubukata, Mikio ; Yanagisawa, Tsutomu ; Sugita, Yutaka ; Kawabata, Yoshinori</creatorcontrib><description>This report describes a 65-year-old woman who developed granulomatous lesions consistent with sarcoidosis during etanercept therapy for rheumatoid arthritis. Hilar and mediastinal lymphadenopathy and multiple nodules in both lung fields developed 21 months after administration of etanercept. Noncaseating epithelioid cell granulomas consistent with sarcoidosis were detected in a lung biopsy specimen and in the parietal pleura obtained via thoracotomy. Diseases showing similar histologic changes were excluded, and a diagnosis of sarcoidosis was made. Etanercept was discontinued, which resulted in symptomatic relief, improvement of oxygenation and radiologic findings. There is substantial evidence of tumor necrosis factor-alpha involvement in the induction and maintenance of granuloma formation; however, we should keep in mind that granulomatous disease, such as sarcoidosis, can develop during treatment with a tumor necrosis factor-alpha blocking agent, such as etanercept.</description><identifier>ISSN: 0918-2918</identifier><identifier>ISSN: 1349-7235</identifier><identifier>EISSN: 1349-7235</identifier><identifier>DOI: 10.2169/internalmedicine.47.0602</identifier><identifier>PMID: 18520114</identifier><language>eng</language><publisher>Japan: The Japanese Society of Internal Medicine</publisher><subject>Aged ; Antirheumatic Agents - adverse effects ; Arthritis, Rheumatoid - drug therapy ; Etanercept ; Female ; Humans ; Immunoglobulin G - adverse effects ; Receptors, Tumor Necrosis Factor ; rheumatoid arthritis ; sarcoidosis ; Sarcoidosis, Pulmonary - chemically induced ; Sarcoidosis, Pulmonary - diagnosis ; Sarcoidosis, Pulmonary - diagnostic imaging ; TNF-α ; Tomography, X-Ray Computed ; Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><ispartof>Internal Medicine, 2008, Vol.47(11), pp.1021-1025</ispartof><rights>2008 by The Japanese Society of Internal Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c614t-6a6c884979a6f773d953d0f2dab06754464ccadd0f15413e0aca68ccde12dd2e3</citedby><cites>FETCH-LOGICAL-c614t-6a6c884979a6f773d953d0f2dab06754464ccadd0f15413e0aca68ccde12dd2e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1877,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18520114$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ishiguro, Takashi</creatorcontrib><creatorcontrib>Takayanagi, Noboru</creatorcontrib><creatorcontrib>Kurashima, Kazuyoshi</creatorcontrib><creatorcontrib>Matsushita, Aya</creatorcontrib><creatorcontrib>Harasawa, Keiji</creatorcontrib><creatorcontrib>Yoneda, Koichiro</creatorcontrib><creatorcontrib>Tsuchiya, Noriko</creatorcontrib><creatorcontrib>Miyahara, Yousuke</creatorcontrib><creatorcontrib>Yamaguchi, Shozaburo</creatorcontrib><creatorcontrib>Yano, Ryozo</creatorcontrib><creatorcontrib>Tokunaga, Daidou</creatorcontrib><creatorcontrib>Saito, Hiroo</creatorcontrib><creatorcontrib>Ubukata, Mikio</creatorcontrib><creatorcontrib>Yanagisawa, Tsutomu</creatorcontrib><creatorcontrib>Sugita, Yutaka</creatorcontrib><creatorcontrib>Kawabata, Yoshinori</creatorcontrib><title>Development of Sarcoidosis during Etanercept Therapy</title><title>Internal Medicine</title><addtitle>Intern. Med.</addtitle><description>This report describes a 65-year-old woman who developed granulomatous lesions consistent with sarcoidosis during etanercept therapy for rheumatoid arthritis. Hilar and mediastinal lymphadenopathy and multiple nodules in both lung fields developed 21 months after administration of etanercept. Noncaseating epithelioid cell granulomas consistent with sarcoidosis were detected in a lung biopsy specimen and in the parietal pleura obtained via thoracotomy. Diseases showing similar histologic changes were excluded, and a diagnosis of sarcoidosis was made. Etanercept was discontinued, which resulted in symptomatic relief, improvement of oxygenation and radiologic findings. There is substantial evidence of tumor necrosis factor-alpha involvement in the induction and maintenance of granuloma formation; however, we should keep in mind that granulomatous disease, such as sarcoidosis, can develop during treatment with a tumor necrosis factor-alpha blocking agent, such as etanercept.</description><subject>Aged</subject><subject>Antirheumatic Agents - adverse effects</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Etanercept</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoglobulin G - adverse effects</subject><subject>Receptors, Tumor Necrosis Factor</subject><subject>rheumatoid arthritis</subject><subject>sarcoidosis</subject><subject>Sarcoidosis, Pulmonary - chemically induced</subject><subject>Sarcoidosis, Pulmonary - diagnosis</subject><subject>Sarcoidosis, Pulmonary - diagnostic imaging</subject><subject>TNF-α</subject><subject>Tomography, X-Ray Computed</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><issn>0918-2918</issn><issn>1349-7235</issn><issn>1349-7235</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkE9PwzAMxSMEYmPwFVBvnDriNE3aIxrjjzRpB8Y5yhJ3y9S1JWmR9u3ptGpIiIst2b_3bD1CIqBTBiJ_dFWLvtLlHq0zrsIpl1MqKLsgY0h4HkuWpJdkTHPIYtaXEbkJYUdpksmcXZMRZCmjAHxM-DN-Y1k3e6zaqC6iD-1N7WwdXIhs5121ieatrtAbbNpotUWvm8MtuSp0GfBu6BPy-TJfzd7ixfL1ffa0iI0A3sZCC5NlPJe5FoWUic3TxNKCWb2mQqacC26Mtv0IUg4JUm20yIyxCMxahsmEPJx8G19_dRhatXfBYFn2D9VdUDmVIJkUrCezE2l8HYLHQjXe7bU_KKDqGJn6G5niUh0j66X3w5Fu3S9_hUNGPbA8AbvQ6g2eAe1bZ0r81xlgqEAZnEmz1V5hlfwASbeKYQ</recordid><startdate>20080101</startdate><enddate>20080101</enddate><creator>Ishiguro, Takashi</creator><creator>Takayanagi, Noboru</creator><creator>Kurashima, Kazuyoshi</creator><creator>Matsushita, Aya</creator><creator>Harasawa, Keiji</creator><creator>Yoneda, Koichiro</creator><creator>Tsuchiya, Noriko</creator><creator>Miyahara, Yousuke</creator><creator>Yamaguchi, Shozaburo</creator><creator>Yano, Ryozo</creator><creator>Tokunaga, Daidou</creator><creator>Saito, Hiroo</creator><creator>Ubukata, Mikio</creator><creator>Yanagisawa, Tsutomu</creator><creator>Sugita, Yutaka</creator><creator>Kawabata, Yoshinori</creator><general>The Japanese Society of Internal Medicine</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20080101</creationdate><title>Development of Sarcoidosis during Etanercept Therapy</title><author>Ishiguro, Takashi ; Takayanagi, Noboru ; Kurashima, Kazuyoshi ; Matsushita, Aya ; Harasawa, Keiji ; Yoneda, Koichiro ; Tsuchiya, Noriko ; Miyahara, Yousuke ; Yamaguchi, Shozaburo ; Yano, Ryozo ; Tokunaga, Daidou ; Saito, Hiroo ; Ubukata, Mikio ; Yanagisawa, Tsutomu ; Sugita, Yutaka ; Kawabata, Yoshinori</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c614t-6a6c884979a6f773d953d0f2dab06754464ccadd0f15413e0aca68ccde12dd2e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Aged</topic><topic>Antirheumatic Agents - adverse effects</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Etanercept</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoglobulin G - adverse effects</topic><topic>Receptors, Tumor Necrosis Factor</topic><topic>rheumatoid arthritis</topic><topic>sarcoidosis</topic><topic>Sarcoidosis, Pulmonary - chemically induced</topic><topic>Sarcoidosis, Pulmonary - diagnosis</topic><topic>Sarcoidosis, Pulmonary - diagnostic imaging</topic><topic>TNF-α</topic><topic>Tomography, X-Ray Computed</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ishiguro, Takashi</creatorcontrib><creatorcontrib>Takayanagi, Noboru</creatorcontrib><creatorcontrib>Kurashima, Kazuyoshi</creatorcontrib><creatorcontrib>Matsushita, Aya</creatorcontrib><creatorcontrib>Harasawa, Keiji</creatorcontrib><creatorcontrib>Yoneda, Koichiro</creatorcontrib><creatorcontrib>Tsuchiya, Noriko</creatorcontrib><creatorcontrib>Miyahara, Yousuke</creatorcontrib><creatorcontrib>Yamaguchi, Shozaburo</creatorcontrib><creatorcontrib>Yano, Ryozo</creatorcontrib><creatorcontrib>Tokunaga, Daidou</creatorcontrib><creatorcontrib>Saito, Hiroo</creatorcontrib><creatorcontrib>Ubukata, Mikio</creatorcontrib><creatorcontrib>Yanagisawa, Tsutomu</creatorcontrib><creatorcontrib>Sugita, Yutaka</creatorcontrib><creatorcontrib>Kawabata, Yoshinori</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Internal Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ishiguro, Takashi</au><au>Takayanagi, Noboru</au><au>Kurashima, Kazuyoshi</au><au>Matsushita, Aya</au><au>Harasawa, Keiji</au><au>Yoneda, Koichiro</au><au>Tsuchiya, Noriko</au><au>Miyahara, Yousuke</au><au>Yamaguchi, Shozaburo</au><au>Yano, Ryozo</au><au>Tokunaga, Daidou</au><au>Saito, Hiroo</au><au>Ubukata, Mikio</au><au>Yanagisawa, Tsutomu</au><au>Sugita, Yutaka</au><au>Kawabata, Yoshinori</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of Sarcoidosis during Etanercept Therapy</atitle><jtitle>Internal Medicine</jtitle><addtitle>Intern. Med.</addtitle><date>2008-01-01</date><risdate>2008</risdate><volume>47</volume><issue>11</issue><spage>1021</spage><epage>1025</epage><pages>1021-1025</pages><issn>0918-2918</issn><issn>1349-7235</issn><eissn>1349-7235</eissn><abstract>This report describes a 65-year-old woman who developed granulomatous lesions consistent with sarcoidosis during etanercept therapy for rheumatoid arthritis. Hilar and mediastinal lymphadenopathy and multiple nodules in both lung fields developed 21 months after administration of etanercept. Noncaseating epithelioid cell granulomas consistent with sarcoidosis were detected in a lung biopsy specimen and in the parietal pleura obtained via thoracotomy. Diseases showing similar histologic changes were excluded, and a diagnosis of sarcoidosis was made. Etanercept was discontinued, which resulted in symptomatic relief, improvement of oxygenation and radiologic findings. There is substantial evidence of tumor necrosis factor-alpha involvement in the induction and maintenance of granuloma formation; however, we should keep in mind that granulomatous disease, such as sarcoidosis, can develop during treatment with a tumor necrosis factor-alpha blocking agent, such as etanercept.</abstract><cop>Japan</cop><pub>The Japanese Society of Internal Medicine</pub><pmid>18520114</pmid><doi>10.2169/internalmedicine.47.0602</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-2918 |
| ispartof | Internal Medicine, 2008, Vol.47(11), pp.1021-1025 |
| issn | 0918-2918 1349-7235 1349-7235 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_907172762 |
| source | J-STAGE Free; MEDLINE |
| subjects | Aged Antirheumatic Agents - adverse effects Arthritis, Rheumatoid - drug therapy Etanercept Female Humans Immunoglobulin G - adverse effects Receptors, Tumor Necrosis Factor rheumatoid arthritis sarcoidosis Sarcoidosis, Pulmonary - chemically induced Sarcoidosis, Pulmonary - diagnosis Sarcoidosis, Pulmonary - diagnostic imaging TNF-α Tomography, X-Ray Computed Tumor Necrosis Factor-alpha - antagonists & inhibitors |
| title | Development of Sarcoidosis during Etanercept Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T13%3A39%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20Sarcoidosis%20during%20Etanercept%20Therapy&rft.jtitle=Internal%20Medicine&rft.au=Ishiguro,%20Takashi&rft.date=2008-01-01&rft.volume=47&rft.issue=11&rft.spage=1021&rft.epage=1025&rft.pages=1021-1025&rft.issn=0918-2918&rft.eissn=1349-7235&rft_id=info:doi/10.2169/internalmedicine.47.0602&rft_dat=%3Cproquest_cross%3E907172762%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=907172762&rft_id=info:pmid/18520114&rfr_iscdi=true |